Your essential biotech, medtech, and pharma recap — no noise, just what matters.

⚡ Executive Takeaway

Three days. That is the distance between now and the opening of the most important oncology meeting of the year. Revolution Medicines' plenary session on Saturday is the headline, but ASCO is far bigger than one presentation. The conference will feature data across ADCs (following two approvals in two weeks: Enhertu in early breast cancer, Datroway in first-line TNBC), next-generation checkpoint inhibitor strategies (after Regeneron's fianlimab miss reset expectations for the LAG-3 class), cell therapy updates (as Lilly's in vivo CAR-T thesis through Kelonia and Orna matures), and emerging modalities including bispecific antibodies and radiopharmaceuticals. We will provide daily coverage of the most significant data throughout the conference. Separately, we owe our readers a catch-up on AstraZeneca's Baxfendy. Approved May 18, Baxfendy is the first new mechanism of action in hypertension in two decades. It inhibits aldosterone synthase, addressing the hormonal root cause of resistant blood pressure rather than the downstream symptoms. AstraZeneca expects more than $5B in peak annual sales, which would make Baxfendy one of the largest cardiovascular launches in years. The 23 million U.S. patients with uncontrolled hypertension despite two or more medications represent the addressable population. 👉 Read Full Analysis

🔮 What To Watch

🔬 Cardiovascular

AstraZeneca's Baxfendy Approved as First New Hypertension Mechanism in Two Decades AZN

What Happened: The FDA approved AstraZeneca's Baxfendy (baxdrostat) on May 18 as the first and only aldosterone synthase inhibitor (ASI) for the treatment of hypertension in combination with other antihypertensive medications. The approval was based on the BaxHTN Phase 3 trial, published in the New England Journal of Medicine, which showed Baxfendy 2 mg lowered systolic blood pressure by 15.7 mmHg (9.8 mmHg placebo-adjusted) in patients with uncontrolled or resistant hypertension on two or more medications.

The Market: Approximately 23 million patients in the U.S. have uncontrolled hypertension despite being on two or more medications. AstraZeneca EVP Ruud Dobber said this population "has seen little therapeutic progress for the past two decades." BaxHTN investigator Dr. Bryan Williams (University College London) said doctors "have been waiting for an innovative medication like Baxfendy for hypertension for many years."

Executive Impact: AstraZeneca expects Baxfendy to generate more than $5B in peak annual sales. The company acquired Baxfendy's developer, CinCor Pharma, for $1.8B in 2023 (121% premium). The drug is also being studied in chronic kidney disease and heart failure, with trials enrolling more than 20,000 patients globally. The approval puts AstraZeneca ahead of Mineralys Therapeutics, which is developing lorundrostat, a rival aldosterone synthase inhibitor currently under FDA review with a PDUFA date in December. Epidemiological data cited by AstraZeneca indicate that a 10 mmHg decrease in systolic blood pressure is associated with roughly 20% lower risk of serious cardiovascular events.

🏢 Corporate & Business Developments

SERB Acquires Hansa Biopharma's Idefirix for $128M

SERB Pharmaceuticals acquired rights to Swedish firm Hansa Biopharma's Idefirix (imlifidase) for $128M upfront on May 24, according to The Pharma Letter. Idefirix is an IgG-cleaving enzyme approved in the EU for desensitization treatment in highly sensitized adult kidney transplant recipients. The deal gives SERB a commercial-stage transplant medicine and expands its specialty care portfolio.

📊 ASCO Preview: Five Sessions Beyond Revolution

Revolution's plenary is the headliner. But these sessions could also move stocks:

📅 The Week Ahead

👉 Read Full Analysis

AstraZeneca has been primarily known for oncology (Enhertu, Tagrisso, Imfinzi) and respiratory (Fasenra, Breztri). The Baxfendy approval gives the company a major franchise in cardiovascular medicine.

The CinCor acquisition in 2023 ($1.8B, 121% premium) was a bet that aldosterone synthase inhibition would prove to be a differentiated mechanism. The BaxHTN data validated that bet: 9.8 mmHg placebo-adjusted systolic reduction is clinically meaningful and large enough to drive adoption. The mechanism is genuinely novel. Every existing hypertension drug (ACE inhibitors, ARBs, calcium channel blockers, diuretics, beta-blockers) works downstream of aldosterone. Baxfendy works upstream, inhibiting the enzyme that produces aldosterone in the first place.

Competition: Mineralys Therapeutics' lorundrostat is the only direct competitor in the aldosterone synthase inhibitor class. It is currently under FDA review with a PDUFA date in December 2026. If approved, the market will split between two ASIs. AstraZeneca has first-mover advantage and deeper commercial infrastructure.

💊 ASCO: The Commercial Stakes

ASCO is not just a scientific conference. It is where commercial narratives are set for the next 12 months:

📊 Section 232 Device Report: The Delay

The Commerce Department's Section 232 report on medical devices was expected in late May based on the September 2025 investigation timeline. As of today, it has not been released. The delay creates uncertainty for the medtech sector. If the report recommends tariffs on imported medical devices, companies with significant overseas manufacturing would face direct cost impact. If it recommends no action, medtech avoids the disruptions pharma has been navigating since April.

🎯 Catalyst Calendar: ASCO Week and Beyond

👉 Visit The Pro Hub

Limited ASCO-week sponsorship slots available (May 29 - June 2). Reach 65,000+ professionals during the biggest oncology event of the year. Learn more →

Is your company listed in the BioMed Nexus directory? 2,104 companies across 14 categories. Claim or upgrade your listing →

Sponsorship slots for 2026 are limited. See packages and pricing →

NEW: BioMed Nexus Signals, weekly sales intelligence for life sciences BD teams. Learn more →